γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma
ConditionMalignant Meningioma
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorNanjing Medical University
About this trial
This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment of malignant meningioma.
Eligibility criteria
Qualifiers
The patient voluntarily signs the informed consent and can complete the follow-up examination, evaluation and treatment;
Age 18-70 years old (both ends included), both male and female;
The histopathological diagnosis was malignant solid tumor;
Tumor recurrence is confirmed by imaging (MRI) or re-biopsy/surgery;
Disqualifiers
Intolerance or allergy to any ingredient or similar drug in the treatment plan planned for this study;
Uncontrolled epilepsy, severe bleeding risk (such as a recent history of cerebral hemorrhage).
Active and/or uncontrolled infections (such as tuberculosis, sepsis, opportunistic infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV) infection, Treponema pallidum (TP) infection).
Severe, uncontrolled systemic autoimmune or inflammatory diseases (such as systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal arteritis, Guillain-Barré syndrome (GBS), amyotrophic lateral sclerosis (ALS)).
Trial design
Treatments tested in this trial
- γδ T-PD-1 Ab cells
Treatment groups
12 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov